

Roughly 4 million people in the United States have treatment-resistant depression. Now, esketamine — the discovery of which was possible with funding from the National Institutes of Health (NIH) and others for medical research in academic medicine — is giving those people hope for relief. Recently approved by the U.S. Food and Drug Administration (FDA), esketamine is the first new therapy in more than 30 years for the treatment of major depression.

MEDICAL DISCOVERY: BUILDING TO A BREAKTHROUGH

The treatment's long path to approval highlights the importance of federal support for medical research in academic medicine.


MEDICAL DISCOVERY: BUILDING TO A BREAKTHROUGH

Breakthroughs are the result of sustained, long-term research and collaborations among academia, industry, and federal partners.

Scientific collaborations across institutions, research fields, and the world are key to developing the groundwork for achieving a breakthrough discovery.

Research at medical schools and teaching hospitals accounts for nearly 55% of National Institutes of Health (NIH) extramural research.

Sustained, predictable funding growth for medical research is vital to bringing discoveries from the bench to the bedside.



Sources:

¹ The Nobel Prize. Otto Loewi: Nobel Lecture. NobelPrize.org. <https://www.nobelprize.org/prizes/medicine/1936/loewi/lecture/>. Accessed Oct. 1, 2019.

² Domino EF, Chodoff P, Corssen G. Pharmacologic effects of Cl-581, a new dissociative anesthetic, in man. *Clin Pharmacol Ther.* 1965 May-Jun;6:279-91.

³ Berman R, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry.* 2000;47(4): 351-354.

⁴ Zarate CA, Singh J, Carlson P, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry.* 2006;63(8):856-864.

⁵ Price R, Nock M, Charney D, Matthews S. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. *Biol Psychiatry.* 2009;66(5):522-526.

⁶ Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. *Biol Psychiatry.* 2012;71(11):939-946.

⁷ H, Choo T, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. *Am J Psychiatry.* 2018;175(4):327-335.

⁸ Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. *JAMA Psychiatry.* 2019;76(9):893-903.

⁹ Johnson & Johnson. Long-term phase 3 study shows esketamine nasal spray plus an oral antidepressant delayed time to relapse in patients with treatment-resistant depression. <https://www.jnj.com/media-center/press-releases/long-term-phase-3-study-shows-esketamine-nasal-spray-plus-an-oral-antidepressant-delayed-time-to-relapse-in-patients-with-treatment-resistant-depression>. Accessed Oct. 1, 2019.

¹⁰ FDA approves esketamine, the first major depression treatment to reach U.S. market in decades. *STAT.* March 5, 2019.